Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

495.91 +4.34 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 965,710
Open 497.00
Bid (Size) 492.32 (1)
Ask (Size) 500.00 (1)
Prev. Close 491.57
Today's Range 491.52 - 498.77
52wk Range 340.20 - 496.93
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
Via InvestorPlace
2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street
Neither of these predictive indicators has ever been wrong when back-tested for more than 150 years! 
Via The Motley Fool

Performance

YTD
+20.69%
+20.69%
1 Month
+5.80%
+5.80%
3 Month
+24.00%
+24.00%
6 Month
+12.68%
+12.68%
1 Year
+38.89%
+38.89%

More News

Read More
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
The 3 Best Neuroscience Biotech Stocks to Buy Now
Via InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:VRTX.
Via Chartmill
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
Via Benzinga
Check Out What Whales Are Doing With VRTX
Via Benzinga
Why the quality investor may take a look at NASDAQ:VRTX.
Via Chartmill
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Via The Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
Via The Motley Fool
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
Via The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Via The Motley Fool
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Via The Motley Fool
3 Top-Rated Gene Editing Stocks Actually Making Money
Via InvestorPlace
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.